Important Safety Information

Compounded semaglutide is prescribed by a licensed clinician for eligible adults when medically appropriate. It may support appetite regulation and metabolic signaling.

• You have a personal or family history of medullary thyroid carcinoma (MTC), or you have Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

Semaglutide carries a boxed warning related to the risk of thyroid C-cell tumors in rodents; relevance to humans is unknown.
Other important risks discussed in FDA labeling for semaglutide products include:

• Pancreatitis (stop and seek medical evaluation if severe abdominal pain occurs)
• Gallbladder problems, kidney problems (particularly if dehydration occurs), and hypoglycemia risk when used with certain diabetes medications (as applicable)
• Allergic reactions (seek urgent care for swelling, trouble breathing, hives)

Many patients experience gastrointestinal effects such as nausea, vomiting, diarrhea, constipation, or stomach discomfort often dose-dependent.

Tell your clinician about all medications and supplements you take. GLP-1 therapies may slow gastric emptying and can affect the absorption of some oral medications.

Inform your clinician if you are pregnant, planning pregnancy, or breastfeeding.

Compounded tirzepatide is prescribed by a licensed clinician for eligible adults when medically appropriate. It may support appetite regulation and metabolic signaling.

• You have a personal or family history of medullary thyroid carcinoma (MTC), or you have Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

Tirzepatide products include a boxed warning related to the risk of thyroid C-cell tumors in rodents; relevance to humans is unknown.
Other important risks discussed in FDA labeling for tirzepatide products include:

• Pancreatitis (seek evaluation for severe abdominal pain)
• Gallbladder problems, kidney problems (especially with dehydration), and hypoglycemia risk when used with certain diabetes medications (as applicable)
• Allergic reactions

Gastrointestinal side effects can occur (nausea, vomiting, diarrhea, constipation), often dose-dependent.

Tell your clinician about all medications and supplements you take. As with GLP-1 therapies, slowed gastric emptying may affect the absorption of some oral medications.

Inform your clinician if you are pregnant, planning pregnancy, or breastfeeding.

NAD+ may be prescribed by a licensed clinician when medically appropriate. NAD+ is sometimes used in clinician-guided wellness/longevity protocols.

• NAD+ products may be compounded depending on formulation and route. Compounded products are not FDA-approved.
• Side effects can vary by individual and route of administration; some people may experience temporary symptoms such as flushing/warmth, nausea, headache, or injection-site reactions.

Tell your clinician if you have cardiovascular conditions, are pregnant or breastfeeding, or take prescription medications - so your clinician can assess whether NAD+ is appropriate for you.

Sermorelin may be prescribed by a licensed clinician when medically appropriate. Historically, sermorelin acetate (Geref) was FDA-approved for specific pediatric use and later discontinued for commercial reasons; compounded sermorelin is used in some settings at the clinician's discretion.

• When used today, sermorelin is often provided via compounding pharmacies; compounded products are not FDA-approved.
• Potential side effects can include injection-site reactions and other effects depending on patient factors and dosing.

Tell your clinician about any history of cancer, endocrine disorders, pregnancy/breastfeeding, or medications - so they can assess appropriateness and monitoring needs.